Welcome and Methods

- Introduction
- Methods
- Table 1. Summary of the Process and Methods for the Guidance Development
- Table 2. Rating System Used to Rate Level of Evidence and Strength of Recommendation
- Table 3. Commonly Used Abbreviations

Test, Evaluate, Monitor

- Testing, Evaluation, and Monitoring of Hepatitis C
- HCV Testing and Linkage to Care
- When and in Whom to Initiate HCV Therapy
- Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens

- Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
- HCV Resistance Primer

Treatment-Naive

- Initial Treatment of Adults with HCV Infection
- Simplified HCV Treatment* for Treatment-Naive Patients Without Cirrhosis
- Simplified HCV Treatment Algorithm for Treatment-Naive Adults With Compensated Cirrhosis
- Treatment-Naive Genotype 1
- Treatment-Naive Genotype 1a Without Cirrhosis
- Treatment-Naive Genotype 1a With Compensated Cirrhosis
- Treatment-Naive Genotype 1b Without Cirrhosis
- Treatment-Naive Genotype 1b With Compensated Cirrhosis
- Treatment-Naive Genotype 2
- Treatment-Naive Genotype 2 Without Cirrhosis
- Treatment-Naive Genotype 2 With Compensated Cirrhosis
- Treatment-Naive Genotype 3
- Treatment-Naive Genotype 3 Without Cirrhosis
- Treatment-Naive Genotype 3 With Compensated Cirrhosis
- Treatment-Naive Genotype 4
- Treatment-Naive Genotype 4 Without Cirrhosis
- Treatment-Naive Genotype 4 With Compensated Cirrhosis
- Treatment-Naive Genotype 5 or 6

Treatment-Experienced

- Retreatment of Persons in Whom Prior Therapy Failed
- Treatment-Experienced Genotype 1
- Peginterferon/Ribavirin-Experienced, Genotype 1a Patients Without Cirrhosis
- Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis
- Peginterferon/Ribavirin-Experienced, Genotype 1b Patients Without Cirrhosis
- Peginterferon/Ribavirin-Experienced, Genotype 1b Patients With Compensated Cirrhosis
<table>
<thead>
<tr>
<th>Unique Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management of Unique &amp; Key Populations With HCV Infection</td>
</tr>
<tr>
<td>Patients With HIV/HCV Coinfection</td>
</tr>
<tr>
<td>Patients With Decompensated Cirrhosis</td>
</tr>
<tr>
<td>Patients Who Develop Recurrent HCV Infection Post Liver Transplantation</td>
</tr>
<tr>
<td>Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors</td>
</tr>
<tr>
<td>Patients with Renal Impairment</td>
</tr>
<tr>
<td>Kidney Transplant Patients</td>
</tr>
<tr>
<td>Management of Acute HCV Infection</td>
</tr>
<tr>
<td>HCV in Pregnancy</td>
</tr>
<tr>
<td>HCV in Children</td>
</tr>
<tr>
<td>Management of Key Populations With Chronic HCV Infection</td>
</tr>
<tr>
<td>Key Populations: Identification and Management of HCV in People Who Inject Drugs</td>
</tr>
<tr>
<td>HCV in Key Populations: Men Who Have Sex With Men</td>
</tr>
<tr>
<td>HCV Testing and Treatment in Correctional Settings</td>
</tr>
</tbody>
</table>

References

- Reference list sorted by first author